Loading...
Market
Story
Pfizer's Talzenna-Xtandi Combo Significantly Prolongs Survival in Final Phase 3 Prostate Cancer Study
Oct 10, 2024, 10:55 AM
Pfizer announced that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly extended overall survival in men with metastatic castration-resistant prostate cancer (mCRPC), according to the final prespecified overall survival analysis of the phase 3 TALAPRO-2 trial. The study demonstrated that the drug combination significantly prolonged patients' lives compared to enzalutamide alone, offering a promising new treatment option for this aggressive form of prostate cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
